Device Industry Grab-Bag Of Provisions In 21st Century Cures Draft
This article was originally published in The Gray Sheet
Device industry advocates have a lot of reading to do. There are more than two dozen provisions with relevance to the medtech sector, many aimed at smoothing the way for product approvals and reimbursement, in a 21st Century Cures discussion draft unveiled by the House Energy and Commerce panel Jan. 27. The initial proposal does not have bipartisan support.
You may also be interested in...
FDA has delivered a draft current good manufacturing practices guidance for combination products, providing details and examples on how the agency regulates drug delivery devices and other drug/device, drug/biological and drug/device/biological products.
Centralized institutional review board approvals for device trials, and removal of HIPAA privacy provisions that block registry data-sharing are among the ideas that are likely to make it into a draft bill planned for release in January as the next step in the House’s 21st Century Cures initiative.
Companies want FDA to expand the bounds of its accelerated device development program, while others urge FDA to be cautious.